Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma

NCT01932385 is registered in ClinicalTrials.gov with Qingdao Central Hospital as lead sponsor.

NCT NCT01932385
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01932385 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma
Lead sponsor
Qingdao Central Hospital
Phase
Phase 2/3
Overall status
Completed
Start date
August 1, 2013
Completion date
July 30, 2016
Enrollment
86 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

liver cancer